Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Plasmid DNA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Plasmid DNA. Displaying page 1 of 1.
    EudraCT Number: 2011-005538-20 Sponsor Protocol Number: BA2011/15/02 Start Date*: 2012-05-15
    Sponsor Name:BioAlliance Pharma
    Full Title: SAFETY AND EFFICACY OF INTRAMUSCULAR ELECTROTRANSFER OF PLASMID AMEP IN PATIENTS SUFFERING FROM ADVANCED OR METASTATIC MELANOMA: AN OPEN-LABEL PHASE I/II CLINICAL TRIAL THE AIMM STUDY (AMEP IN MET...
    Medical condition: Treatment of patients suffering from advanced or metastatic melanoma (stages III, IV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002849-40 Sponsor Protocol Number: DermHivImm Start Date*: 2006-03-29
    Sponsor Name:Swedish Institute for Infectious Disease Control
    Full Title: Active immunotherapy against HIV during highly active anti-retroviral therapy followed by repeated treatment interruptions, VAC 09.
    Medical condition: Treatment of HIV infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009863-75 Sponsor Protocol Number: CEAEP_2009-05-29 Start Date*: 2009-08-26
    Sponsor Name:Karolinska Institutet/ Hospital
    Full Title: El-porCEA: Assessment of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer.
    Medical condition: Colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002359-18 Sponsor Protocol Number: PEDVAC Start Date*: 2008-04-23
    Sponsor Name:Swedish Institute for Infectious Disease Control
    Full Title: DNA vaccination in HIV-vertically infected children
    Medical condition: Pazienti con infezione verticale da HIV di eta' compresa tra 4 -16 anni di ambo i sessi.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053500 Human immunodeficiency virus transmission LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022960-10 Sponsor Protocol Number: CVC-202 Start Date*: 2011-03-30
    Sponsor Name:ChronTech Pharma AB
    Full Title: A Phase II Open-Label, Randomized, Parallel group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination with Electroporation followed by Standard of Care in Chroni...
    Medical condition: Treatment of chronic infections caused by hepatitis C virus genotype 1 strains
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004120-21 Sponsor Protocol Number: LX01-315 Start Date*: 2008-02-27
    Sponsor Name:Vical Incorporated
    Full Title: A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metas...
    Medical condition: Recurrent metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Ongoing) NL (Prematurely Ended) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002901-33 Sponsor Protocol Number: CVC-201 Start Date*: 2007-08-10
    Sponsor Name:Tripep AB
    Full Title: A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered ChronVac-C® in Combination with Electroporation in Chronic Hepatitis C Virus Genotype ...
    Medical condition: Treatment of chronic infections caused by hepatitis C virus genotype 1 strains
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003734-20 Sponsor Protocol Number: COV-1/2-01 Start Date*: 2021-02-03
    Sponsor Name:Takis S.r.l.
    Full Title: A Phase I/II study to assess the safety and immunogenicity of COVID-eVax, a candidate plasmid DNA vaccine for COVID-19, in healthy adult volunteers.
    Medical condition: COVID-19 prevention.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002844-10 Sponsor Protocol Number: SCIB1-002 Start Date*: 2019-01-24
    Sponsor Name:Scancell Ltd
    Full Title: A Phase 2, Multicenter, Open-Label Study of SCIB1 in Patients with Advanced Unresectable Melanoma Receiving Pembrolizumab
    Medical condition: Advanced unresectable melanoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:17:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA